Adult patients with refractory or relapsed follicular lymphoma research hub

A Phase II, single arm, multicenter open label trial to determine the efficacy and safety of tisagenlecleucel (CTL019) in adult patients with refractory or relapsed follicular lymphoma

This study is for adults in the UK with a type of cancer called follicular lymphoma that has come back or not responded to previous treatments. It investigates a new cell therapy called tisagenlecleucel to see how well it works and if it's safe.